Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.1
Journals
JPM
Special Issues
Personalized Medicine in Retinal Diseases
share announcement

Personalized Medicine in Retinal Diseases

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Clinical Medicine, Cell, and Organism Physiology".

Deadline for manuscript submissions: 25 February 2026 | Viewed by 2112

Special Issue Editor

Dr. Henrik Faatz

E-Mail Website
Guest Editor
1. Department of Ophthalmology, St. Franziskus Hospital, 48145 Münster, Germany
2. Achim Wessing Institute for Diagnostic Ophthalmology, Duisburg–Essen University, 45147 Essen, Germany
Interests: age-related macular degeneration (AMD); retinal vascular occlusions; intravitreal injections (IVOM); retinal and vitreous surgery

Special Issue Information

Dear Colleagues,

Retinal diseases are among the most common causes of irreversible blindness. In older adults, it is often the late stage of age-related macular degeneration (AMD), while in working-age individuals, diabetic retinopathy, chronic central serous chorioretinopathy, secondary neovascularizations, or a variety of genetic diseases are more frequently responsible. Since the introduction of anti-VEGF therapy, the prognosis for patients with neovascularizations has significantly improved. However, there is also a great variability in disease progression, with some patients requiring only a few treatments and maintaining good vision in the long term, while others need monthly therapy for decades and experience a significant decline in vision due to complications such as macular hemorrhages, tears of the retinal pigment epithelium, or atrophy of photoreceptors and pigment epithelial cells. Especially with the development of new anti-VEGF agents, the identification of biomarkers that can enable more individualized therapy would be desirable. This also applies to patients with diabetic retinopathy and diabetic macular edema, as well as patients with secondary neovascularization, who are currently treated non-specifically with the same substances. Additionally, with the approval of complement inhibitors, treatment for geographic atrophy (GA) is now available. Even in this late form, several different disease patterns with varying progression rates are already known. Further identification of individual biomarkers could also improve therapy management here. This Special Issue of the Journal of Personalized Medicine aims to present outstanding research dedicated to the individualized investigation of biomarkers for disease progression or therapy response in retinal diseases.

Dr. Henrik Faatz
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • retinal disease
  • age-related macular degeneration
  • diabetic retinopathy
  • gene therapy
  • retinal biomarker
  • personalized medicine
  • retinal imaging

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

12 pages, 2852 KiB  
Article
Real-Life Treatment Intervals and Morphological Outcomes Following the Switch to Faricimab Therapy in Neovascular Age-Related Macular Degeneration
by Katrin Löw, Vasilena Sitnilska, Yuhe Tang, Jeany Q. Lammert, Tim U. Krohne and Lebriz Altay
J. Pers. Med. 2025, 15(5), 189; https://doi.org/10.3390/jpm15050189 - 6 May 2025
Viewed by 249
Abstract
Objectives: To evaluate the efficacy of faricimab in patients with neovascular age-related macular degeneration (nAMD) that did not respond to other VEGF inhibitors. Methods: This retrospective study included the eyes of patients diagnosed with nAMD who had been switched to faricimab [...] Read more.
Objectives: To evaluate the efficacy of faricimab in patients with neovascular age-related macular degeneration (nAMD) that did not respond to other VEGF inhibitors. Methods: This retrospective study included the eyes of patients diagnosed with nAMD who had been switched to faricimab treatment due to the persistence of intraretinal fluid (IRF) and/or subretinal fluid (SRF), despite monthly anti-VEGF treatment with aflibercept, bevacizumab, or ranibizumab using the treat and extend regimen, and who had received at least three faricimab injections following the switch. Best-corrected visual acuity (BCVA) measurement and optical coherence tomography (OCT) analysis were performed at each visit, and the OCT results were graded by two independent readers. Results: We included 41 eyes of 39 patients (21 male, 18 female) with a mean age of 80.5 ± 8.1 years. The median duration of anti-VEGF treatment prior to the switch to faricimab was 5.0 years, with a median of 53 injections. Complete resolution of IRF and SRF was observed after the first dose of faricimab in 12 eyes (29.3%) and after the third dose in 15 eyes (36.6%). Twenty-eight eyes reached a follow-up time after a switch of at least 12 months, with a median of 10 faricimab injections. Of these 28 eyes, 10 eyes (35.7%) exhibited complete IRF/SRF resolution; treatment intervals were extended beyond 4 weeks in 21 eyes (80.7%), and 8 eyes (28.6%) presented complete IRF/SRF resolution under extended treatment intervals at month 12. Central retinal thickness after 12 months was reduced from a median of 368.0 µm to 297.5 µm (p < 0.001), and the BCVA remained stable (p = 0.057). No adverse events were reported throughout the entire treatment period. Conclusions: In nAMD patients with poor anti-VEGF treatment response, complete and fast fluid resolution and the extension of treatment intervals can be reached by switching to faricimab, even after years of prior unsuccessful therapy. Full article
(This article belongs to the Special Issue Personalized Medicine in Retinal Diseases)
►▼ Show Figures

Figure 1

12 pages, 554 KiB  
Article
Impact of Anti—Vascular Endothelial Growth Factor Treatment on Neovascular Age-Related Macular Degeneration with and without Retinal Pigment Epithelial Detachment: A Real-World Study
by Yu-Wei Kuo, Cheng-Yung Lee, Yi-Ting Hsieh, Chung-May Yang, Tzyy-Chang Ho, Tso-Ting Lai and Chang-Hao Yang
J. Pers. Med. 2024, 14(10), 1041; https://doi.org/10.3390/jpm14101041 - 28 Sep 2024
Viewed by 1404
Abstract
Background/Objectives: This study evaluates the impact of anti-vascular endothelial growth factor (anti-VEGF) treatment on neovascular age-related macular degeneration (nAMD) with and without pigment epithelial detachment (PED) over a one-year period. Methods: Conducted at a tertiary referral center in Taiwan, this retrospective analysis included [...] Read more.
Background/Objectives: This study evaluates the impact of anti-vascular endothelial growth factor (anti-VEGF) treatment on neovascular age-related macular degeneration (nAMD) with and without pigment epithelial detachment (PED) over a one-year period. Methods: Conducted at a tertiary referral center in Taiwan, this retrospective analysis included 88 eyes treated with intravitreal aflibercept injections. Patients were categorized into four groups based on the presence or absence of PED at baseline and 12 months post-treatment. Results: Significant reductions in central macular thickness (CMT) and PED height were observed, although no statistical difference was found in best-corrected visual acuity (BCVA). The presence or type of PED did not negatively impact visual outcomes. Among nAMD patients with persistent PED throughout the first year of anti-VEGF treatment, linear regression analysis showed that mixed-type PED revealed poor final BCVA compared to those with serous PED. The analysis also identified older age and poorer initial BCVA as predictors of less favorable visual outcomes. Conclusions: This study highlights the effectiveness of anti-VEGF therapy in real-world settings and offers insights into factors influencing visual outcomes for nAMD patients with PED. Full article
(This article belongs to the Special Issue Personalized Medicine in Retinal Diseases)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop